{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T10:15:39Z","timestamp":1695896139780},"reference-count":25,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1321,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1111\/j.1742-1241.2011.02864.x","type":"journal-article","created":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T07:14:51Z","timestamp":1326957291000},"page":"139-145","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic effect of \u03b1-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio"],"prefix":"10.1155","volume":"66","author":[{"given":"C.-H.","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-D.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-C.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,1,19]]},"reference":[{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","article-title":"Combination treatment with an alphablocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study","volume":"169","author":"Athanasopoulos","year":"2003","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosine for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.urology.2009.12.010","article-title":"Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams","volume":"75","author":"Chung","year":"2010","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/nau.20923","article-title":"The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia","volume":"30","author":"Chung","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MOU.0b013e32834100ef","article-title":"An algorithm for medical management in male lower urinary tract symptoms","volume":"21","author":"Djavan","year":"2011","journal-title":"Curr Opin Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1742-1241.2010.02611.x","article-title":"Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review","volume":"65","author":"Kaplan","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB12|cit12","author":"Oelke","year":"2011","journal-title":"Uroweb"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","article-title":"The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update","volume":"60","author":"Athanasopoulos","year":"2011","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOU.0b013e3283330862","article-title":"Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia","volume":"20","author":"Chapple","year":"2010","journal-title":"Curr Opin Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1742-1241.2011.02638.x","article-title":"Diagnostic value of International Prostate Symptom Score voiding-to-storage subscore ratio in male lower urinary tract symptoms","volume":"65","author":"Liao","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2005.07.014","article-title":"Interstitial Cystitis Clinical Trials Group Responsiveness of symptom scales for interstitial cystitis","volume":"67","author":"Mayer","year":"2006","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4065\/83.9.1002","article-title":"Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study","volume":"83","author":"MacDiarmid","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1464-410X.2010.09359.x","article-title":"Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an \u03b1-blocker: effect of baseline prostate-specific antigen concentration","volume":"106","author":"Chapple","year":"2010","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.06.032","article-title":"Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size","volume":"55","author":"Roehrborn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1742-1241.2007.01625.x","article-title":"Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions","volume":"62","author":"Staskin","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/nau.20586","article-title":"Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity","volume":"28","author":"Ronchi","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2011.02864.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1742-1241.2008.01785.x","article-title":"Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management","volume":"62","author":"Emberton","year":"2008","journal-title":"Int J Clin Pract"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2011.02864.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2011.02864.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:00Z","timestamp":1643349840000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2011.02864.x"}},"subtitle":["Therapeutic effect based on IPSS subscore ratio"],"short-title":[],"issued":{"date-parts":[[2012,1,19]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02864.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,19]]}}}